Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Active not recruiting × azeliragon × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 170 Nivolumab 131 Specimen Handling 110 Carboplatin 110 Cyclophosphamide 101 Magnetic Resonance Spectroscopy 95 Paclitaxel 90 Biopsy 83 Cisplatin 80 durvalumab 77 Radiotherapy 76 Dexamethasone 76 atezolizumab 68 Ipilimumab 63 Lenalidomide 59 Gemcitabine 59 Rituximab 53 Docetaxel 52 Doxorubicin 51 Bevacizumab 50 olaparib 49 Fluorouracil 46 Oxaliplatin 45 Prednisone 42 Capecitabine 41 Etoposide 40 Radiosurgery 39 Radiation 39 Leucovorin 37 Temozolomide 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05986851 2024-09-05

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡